Therapy News and Research

RSS

Sequella receives FDA fast track status for pulmonary tuberculosis drug

Sequella, Inc. has announced it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SQ109, the company's proprietary lead drug candidate for treatment of pulmonary tuberculosis (TB).

22 Jan 2007

Improved effectiveness of partner notification for patients with sexually transmitted infections

Doctors should encourage patients with sexually transmitted infections to tell their partners to seek treatment and, in some cases, provide home testing kits or drugs to help reduce infection rates, says a new study on British Medical Journal website.

18 Jan 2007

Advanced Neuromodulation Systems receives European approval for Rapid Programmer

Advanced Neuromodulation Systems (ANS), the neuromodulation business of St. Jude Medical, Inc., has announced European CE Mark approval for its newest clinician programming platform, Rapid Programmer 3.0 for spinal cord stimulation (SCS), an advanced therapy for managing chronic pain.

18 Jan 2007

Combination therapy spares some head and neck patients from surgery

Giving patients with head and neck cancer a combination of chemotherapy and radiation therapy controls the cancer and allows many patients to avoid additional surgery to the neck.

18 Jan 2007

Cetuximab may prolong survival for head and neck cancer patients

Preliminary findings show adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer live longer, according to a study presented at the plenary session of the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.

18 Jan 2007

Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients

The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.

18 Jan 2007

Nanoparticles yield delivery tools for therapeutic nucleic acids

Cancer researchers hold great hope that nucleic acid-based therapeutics, such as anticancer genes, antisense oligonucleotides, and small interfering RNA (siRNA) molecules, will prove to be powerful antitumor agents.

16 Jan 2007

Selective marker found to indicate aggressive form of breast cancer

Researchers have linked a structural protein called nestin to a particularly deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better treatment.

16 Jan 2007

Moog to acquire ZEVEX International

Moog Inc has announced that it has entered into a definitive agreement to acquire ZEVEX International, Inc for $13.00 in cash per share of ZEVEX common stock.

14 Jan 2007

Piolitazone shows promise for preventing brain injury from radiation therapy

Researchers at Wake Forest University School of Medicine are the first to report that in animal studies, a common diabetes drug prevents the memory and learning problems that cancer patients often experience after whole-brain radiation treatments.

10 Jan 2007

DNA methylation and breast cancer

A new study using mastectomy tissue shows that precancerous changes can occur in normal-appearing areas of the breast as distant as two inches from a tumor's edge.

10 Jan 2007

Enzyme PMR1 reveals kind side

New research shows that a recently discovered enzyme that destroys the messenger RNA (mRNA) for some proteins can also help to protect the mRNA during times of stress. The response might help cancer cells survive chemotherapy and radiation therapy.

10 Jan 2007

Several specific genetic alterations associated with development of smoking-related cancers

Preliminary research indicates that several specific genetic alterations are associated with the development of smoking-related head and neck skin cancers, according to a report in the January 10 issue of JAMA: The Journal of the American Medical Association.

9 Jan 2007

New hope for Krabbe disease sufferers

By all expectations, it shouldn't have worked as well as it did. A combination of bone marrow transplantation and gene therapy greatly lengthened the lives of laboratory mice doomed by a rapidly progressing, fatal neurodegenerative disorder also found in people.

9 Jan 2007

Simple blood test for the protein NT-proBNP predicts cardiac events

A simple blood test for the protein NT-proBNP accurately predicts the risk of heart attack, heart failure, stroke, and death in patients with known cardiovascular disease, according to a study led by a researcher at the San Francisco VA Medical Center.

9 Jan 2007

Viral Genetics identifies two key peptides for potential HIV/AIDS drug

Viral Genetics has identified two key peptides involved in its thymus nuclear protein or "TNP" technology currently under development for the treatment of HIV/AIDS.

9 Jan 2007

Advancing medical technology increases health-care costs

Advances in medical technology are a main factor driving the trend of increasing health care costs, and industry stakeholders agree that improved evaluation methods are needed to better measure the benefits and risks of new technologies and procedures in order to avoid misallocation of health care dollars.

9 Jan 2007

Modified skin cells that may help protect cultured skin substitutes from infection

Cincinnati burn researchers have created genetically modified skin cells that, when added to cultured skin substitutes, may help fight off potentially lethal infections in patients with severe burns.

9 Jan 2007

Allergic reactions to insulin have declined and Continuous Subcutaneous Insulin Infusion could reduce them further

A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification of animal insulin and the introduction of human recombinant insulin.

8 Jan 2007

Cell therapy for Parkinson's

Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.

8 Jan 2007